Prevention by intravesical hyaluronic acid (Cystistat®) of acute radiation-induced cystitis in radiotherapeutic management of cervical cancer E. González.

Slides:

Advertisements

Similar presentations

CLINICAL TRIALS IN CERVICAL CANCER Cancer Institute (WIA) experience.

Advertisements

بسم الله الرحمن الرحيم ﴿و قل رب زدنى علماً﴾ صدق الله العظيم.

I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days E V A L U A.

Endometrial Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”

A phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM) ( #1008) V. Stieber.

Dr.Sandeep.M Junior resident Dr.Ajaykumar Prof & HOD.

Radiotherapeutic Option in Management of Hepatocellular Carcinoma

Age-standardized incidence of cervical cancer in selected worldwide countries Zimbabwe, Harare Peru, Trujilo India, Madras Colombia, Cali Argentina India,

H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.

Anal Cancer Rob Glynne-Jones Mount Vernon Cancer Centre on behalf of NCRI anal cancer subgroup.

Morbidity / Complications

Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;

CET Cancer Center Oakland California High Dose Rate (HDR) Brachytherapy Gynecological Cancer D. Jeffrey Demanes M.D

A single-arm phase II trial in p treated with C, D and B (15 mg/kg) every 3 weeks followed by B showed a promising efficacy, in terms of progression free.

Radiothérapie Hypofractionnée et Cancer de Prostate

Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin- Induced Sensory Neurotoxicity, N08CB.

A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.

Impact of overall treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemo-radiation and image-guided adaptive.

Routine Use of Intraoperative Ultrasound Guidance during Intracavitary Brachytherapy Applicator Placement in Cervical Cancer: the University of Alabama.

Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.

Pneumonectomy for Locally Advanced Lung Cancer after Neoadjuvant Concurrent Chemo-radiation Therapy K. Okabe, H. Tao, T. Tanaka, T. Hayashi, K. Yoshiyama,

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

Phase II Trial of Continuous Course Re- irradiation Concurrent with Weekly Cisplatinum and Cetuximab for Recurrent Squamous Cell Carcinoma of The Head.

Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,

Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.

Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:

TEMPLATE DESIGN © ONCOLOGICAL REFERRAL PATTERNS OF GYNAECOLOGICAL CANCER PATIENTS OVER 2010 – 2011 THE NEED FOR GYNAECOLOGIC.

PROSTATE CANCER: RADIATION THERAPY APPROACHES ANDREW L. SALNER, MD FACR DIRECTOR HELEN & HARRY GRAY CANCER CENTER HARTFORD HOSPITAL, CT.

Phase Ⅱ Trial of Docetaxel and Cisplatin Neoadjuvant Chemotherapy Followed by Intensity-modulated Radiotherapy with Concurrent Cisplatin in Locally Advanced.

Permanent Interstitial Implants Ideal strategy to curatively manage small volume gynecologic malignancies Can deliver high cumulative radiation dose to.

Efficacy of sodium hyaluronate in the management of chemical and radiation cystitis Sommariva et al. Minerrva Urol Nefrol 2010.

Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from.

Mahatma Gandhi Cancer Hospital and Research Institute Dr P. S. Bhattacharyya, MD Radiation Oncologist. Elekta Synergy CT Simulator Flexitron HDR.

THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.

Adjuvant High-Dose-Rate Brachytherapy Alone for Stage I/II Endometrial Adenocarcinoma using a 4-Gray versus 6-Gray Fractionation Scheme Marie Lynn Racine,

Long-Term versus Short-Term Androgen Deprivation Combined with High-Dose Radiotherapy for Intermediate and High Risk Prostate Cancer: Preliminary Results.

FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.

Outcomes of Stereotactic Ablative Radiotherapy (SABR) for a Second Primary Lung Cancer (SPLC): Evidence in Support of Routine CT Surveillance C. J.A. Haasbeek,

Adjuvant treatment for endometrial cancer Ameri A Associate Professor of Radiation Oncology Shahid Beheshti University of Medical Sciences Dec Pars.

IMPACT OF PHYSICAL DOSE RATE EFFECT ON THE LONG TERM RESULTS OF THE CF-252 BRACHYTHERAPY OF CERVIX CARCINOMA E. Janulionis; K.P.Valuckas; V.Atkocius; V.Samerdokiene.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

To investigate the acute toxicity of 3D conformal concurrent chemo RT (Keeping PTV Dmax

ENDOMETRIAL CARCINOMA UPDATES Dr Marco Matos Gold Coast Cancer Care, Gold Coast University Hospital and Pacific Private Oncology Group.

The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.

Patient and Tumour Characteristics Median age 60 years (26-92) Karnofsky Status:median 90 (50-100) Histology:SCC: n=120 (83%) Tumor size: ≥ 5 cm: n=78.

Department of Clinical Radiotherapy, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK R4 한재준 1.

Conflicts of Interest Nil conflicts of interest..

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

PURPOSE PURPOSE METHODSMETHODS CONCLUSIONSCONCLUSIONS Long-term results of daily HDR brachytherapy in the postoperative setting of endometrial carcinoma.

Image Guided Interstitial Brachytherapy For Locally Advanced Gynaecological Cancer With A MUPIT Applicator M.A.D. Haverkort, MD 1, E. Van der Steen - Banasik,

Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.

Radiation therapy for Early Stage Prostate Cancer

THREE OR FOUR FRACTIONS PER WEEK IN POSTOPERATIVE HIGH DOSE RATE BRACHYTHERAPY (HDRBT) FOR ENDOMETRIAL CARCINOMA (EC). Rovirosa A1, Vargas M1, Ascaso C2,

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Comparative Results of Vaginal Relapses and Toxicity of Three 192-Ir HDR brachytherapy (BT) Schedules in Postoperative Endometrial Carcinoma (EC). Rovirosa.

Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.

Institute of Oncology “Ion Chiricuță”, Cluj, Romania

Figure 1. The (a) anterior–posterior and (b) right-lateral fields and (c, d) the isodose distributions of two axial planes in one patient with T2 stage.

RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.

Evaluate the results of concomitance chemoradiotherapy postoperative treatment for rectal cancer in stage II-III At K Hospital from 2012 to 2016 Speaker:

Adjuvant Radiation is Required for Gastric Cancer

ACT II: The Second UK Phase III Anal Cancer Trial

Management of endometrial cancer found on routine hysterectomy for benign disease Prof Dr M Anıl Onan MAY ANTALYA.

Neoadjuvant Adjuvant Curative Palliative

Presentation transcript:

Prevention by intravesical hyaluronic acid (Cystistat®) of acute radiation-induced cystitis in radiotherapeutic management of cervical cancer E. González Patiño, N. Salvador Garrido, E. Castro Gómez, R. Miguens Duarte, A. Varela Pazos, E. Canosa Santos, C. Porto Vázquez. Radiation Oncology Department. Complexo Hospitalario Universitario. Hospital Clínico. Santiago de Compostela. Spain. One of the main objectives in the radiotherapeutic management of cervical cancer is to the treat in a period nonsuperior to 8 weeks, since there is evidence that by every day that surpasses this period of time, there is a 1% of loss in the probability of both tumor response and tumoral control. In this therapeutic strategy is fundamental to avoid and control the appearance of secondary toxicity to the treatment that causes these interruptions. The incidence of acute radiation-induced cystitis (RIC) during treatment varies, in the literature, between 3-6.7%. Concomitant use of chemotherapeutic agents may work synergistically to increase the risk of developing bladder injury from radiation. The treatment with intravesical hyaluronic acid (IV-HA) (Cystistat®) has demonstrated its effectiveness in different forms from interstitial cystitis. We present our initial experience in the use if IV-HA instillations in the prevention of RIC in patients diagnosed of cervical neoplasia and treated with a curative chemo-radiotherapy protocol. CERVICAL CANCER Patients data Patients 14 Median age 61,5 y. (39-74) Pathology epidermoid carcinoma: 4. adenocarcinoma: 3. Stage (FIGO) IB (> 4 cm): 2 ; II B: 6 ; III A: 1 ; III B: 3 Treatment schedule week of treatment IV-HA - 1 Stage IIB cervical carcinoma PELVIC RADIOTHERAPY CDDP External beam radiotherapy (EBRT): 45 – 50 Gy/5-5,5 w (1,8 Gy/fx) IV-HA 1 Concomitant (weekly) chemotherapy: CISPLATINUM (CDDP): 40 mg/m2 CDDP HDR brachytherapy (HDR-BT): 5 x 5,5 Gy to (point A) If posible, HDR starts at the four week. (the day of HDR-brachytherapy: no EBRT or chemotherapy are administred) 2 IV-HA IV-HA CDDP Intravesical hialuronic acid (IV-HA) (Cystistat®) One instillation in the week -1. Weekly instilations during EBRT. One instillation on each brachytherapy insertion, during the treatment aplication, in order to maintain the same vesical volume (50 ml) used for the planning CT. A weekly instillation for the following four weeks to the conclusion of treatment. 3 IV-HA CDDP IV-HA 4 HDR-BT IV-HA CDDP 5 IV-HA HDR-BT IV-HA Evaluation of bladder toxicity (RTOG/EORTC scale) (previously to each IV-HA instilation) HDR-BT IV-HA GRADE 1 2 3 4 PATIENTS (#) 2 (*) 4(*) -- 6 HDR-BT IV-HA HDR-BT IV-HA 7 (*) HDR-BT treatment was started no patients developed grade III toxicity. no treatment was disrupted due bladder toxicity all patients were free of vesical toxicity after the 2nd week of conclusion of treatment IV-HA 8 (X 4 weeks) Although these are preliminary results and prospective studies are necesary to confirm this effect, in this short serie of patients the use of IV-HA instillations had a protective effect on the vesical mucosa in the prevention of RIC, allowing finalizing the treatment in the scheduled time. In our opinion, treatment must be started from the begining of chemo-radiotherapy schedule treatment, since the radiation injury takes place already fron initials days of treatment. The study in ongoing in order to have more complete data in the next future.